Care Property Invest Valuation
Is 8OM undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 8OM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 8OM (€12.34) is trading below our estimate of fair value (€38.87)
Significantly Below Fair Value: 8OM is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 8OM?
Key metric: As 8OM is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 8OM's PS Ratio? | |
|---|---|
| PS Ratio | 6.5x |
| Sales | €70.18m |
| Market Cap | €454.96m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 9.2x |
| Enterprise Value/EBITDA | 11.2x |
| PEG Ratio | 3.1x |
Price to Sales Ratio vs Peers
How does 8OM's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.7x | ||
HABA Hamborner REIT | 4.9x | 1.7% | €515.7m |
AOX alstria office REIT-AG | 5.2x | -1.5% | €1.2b |
DKG Deutsche Konsum REIT-AG | 1.3x | -7.4% | €135.4m |
SNGYO Sinpas Gayrimenkul Yatirim Ortakligi | 3.5x | n/a | ₺13.2b |
8OM Care Property Invest | 6.5x | 3.9% | €455.0m |
Price-To-Sales vs Peers: 8OM is expensive based on its Price-To-Sales Ratio (6.5x) compared to the peer average (3.7x).
Price to Sales Ratio vs Industry
How does 8OM's PS Ratio compare vs other companies in the European Residential REITs Industry?
| 1 Company | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: 8OM is good value based on its Price-To-Sales Ratio (6.5x) compared to the European Residential REITs industry average (8.9x).
Price to Sales Ratio vs Fair Ratio
What is 8OM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 6.5x |
| Fair PS Ratio | 10.5x |
Price-To-Sales vs Fair Ratio: 8OM is good value based on its Price-To-Sales Ratio (6.5x) compared to the estimated Fair Price-To-Sales Ratio (10.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €12.34 | €15.63 +26.6% | 4.7% | €16.50 | €14.50 | n/a | 4 |
| Nov ’25 | €12.24 | €15.50 +26.6% | 4.6% | €16.50 | €14.50 | n/a | 4 |
| Oct ’25 | €14.10 | €15.50 +9.9% | 4.6% | €16.50 | €14.50 | n/a | 4 |
| Sep ’25 | €14.10 | €15.50 +9.9% | 4.6% | €16.50 | €14.50 | n/a | 4 |
| Aug ’25 | €13.50 | €15.50 +14.8% | 4.6% | €16.50 | €14.50 | n/a | 4 |
| Jul ’25 | €13.62 | €15.50 +13.8% | 4.6% | €16.50 | €14.50 | n/a | 4 |
| Jun ’25 | €13.70 | €15.50 +13.1% | 4.6% | €16.50 | €14.50 | n/a | 4 |
| May ’25 | €13.16 | €15.13 +14.9% | 2.7% | €15.50 | €14.50 | n/a | 4 |
| Apr ’25 | €12.52 | €15.13 +20.8% | 2.7% | €15.50 | €14.50 | n/a | 4 |
| Mar ’25 | €11.98 | €15.25 +27.3% | 1.6% | €15.50 | €15.00 | n/a | 4 |
| Feb ’25 | €12.76 | €15.25 +19.5% | 1.6% | €15.50 | €15.00 | n/a | 4 |
| Jan ’25 | €14.34 | €15.13 +5.5% | 4.9% | €16.00 | €14.00 | n/a | 4 |
| Dec ’24 | €12.54 | €15.13 +20.6% | 4.9% | €16.00 | €14.00 | n/a | 4 |
| Nov ’24 | €11.48 | €15.38 +33.9% | 2.7% | €16.00 | €15.00 | €12.24 | 4 |
| Oct ’24 | €11.22 | €16.38 +45.9% | 12.8% | €20.00 | €15.00 | €14.10 | 4 |
| Sep ’24 | €12.00 | €16.88 +40.6% | 12.3% | €20.00 | €15.00 | €14.10 | 4 |
| Aug ’24 | €12.60 | €16.67 +32.3% | 14.1% | €20.00 | €15.00 | €13.50 | 3 |
| Jul ’24 | €11.84 | €19.00 +60.5% | 15.5% | €22.00 | €15.00 | €13.62 | 3 |
| Jun ’24 | €12.40 | €19.00 +53.2% | 15.5% | €22.00 | €15.00 | €13.70 | 3 |
| May ’24 | €13.08 | €19.50 +49.1% | 23.1% | €24.00 | €15.00 | €13.16 | 2 |
| Apr ’24 | €12.40 | €19.50 +57.3% | 23.1% | €24.00 | €15.00 | €12.52 | 2 |
| Feb ’24 | €14.12 | €29.50 +108.9% | 18.6% | €35.00 | €24.00 | €12.76 | 2 |
| Jan ’24 | €15.48 | €35.33 +128.3% | 5.8% | €38.00 | €33.00 | €14.34 | 3 |
| Dec ’23 | €14.60 | €34.63 +137.2% | 6.2% | €38.00 | €32.50 | €12.54 | 4 |
| Nov ’23 | €16.18 | €34.63 +114.0% | 6.2% | €38.00 | €32.50 | €11.48 | 4 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Argan
€1.7b
Engages in designing, building, developing, owning, leasing, and managing logistical platforms in France.
871
€64.80
7D
-3.1%
1Y
-11.8%
Allied Properties Real Estate Investment Trust
CA$2.5b
Allied is a leading owner-operator of distinctive urban workspace in Canada's major cities.
5G8
CA$12.23
7D
-0.6%
1Y
5.9%
NSI
€376.7m
A specialist commercial property investor and the only listed real estate investment trust (REIT) focused on well-located offices in economic growth regions in The Netherlands.
N4RN
€19.56
7D
0.3%
1Y
14.1%